Another new drug offers hope for Stargardt patientsPosted: Monday 29 January 2024
Another drug to potentially treat Stargardt has shown positive results in slowing down the progression of the disease in a recent trial.
Alkeus Pharmaceuticals has revealed promising early results from its TEASE-3 clinical trial of the drug ALK-001. When given to young people in the early stages of the disease, it appears to be able to halt progression before retinal damage and vision loss occurs.
Similar to Remofuscin, the trial looked at early-stage Stargardt disease. It saw three teenagers treated with the drug and during the two to six years of treatment none of the trial participants saw any deterioration in their condition.
Projections suggested that without treatment, the participants would typically experience vision loss within two years, similar to their untreated siblings with identical genetic mutations.
Leonide Saad, CEO of Alkeus Pharmaceutical is hopeful about gildeuretinol acetate stopping sight loss from Stargardt disease, especially if treated early.
In addition to the Stargardt trials, Alkeus Pharmaceuticals is also testing the drug on 200 people with late-stage dry age-related macular degeneration (AMD), also known as geographic atrophy (GA).
For more information, visit Alkeus Pharmaceutical's website.
Stargardt disease is a genetic condition caused by a tiny alteration in a single gene. It is the most common form of juvenile macular dystrophy.
Age-related macular degeneration (AMD) usually affects people over 50 but can happen earlier. AMD is the biggest cause of sight loss in the UK, affecting more than 700,000 people.
Beating macular disease through funding medical research and improving the lives of those living with macular disease.
We provide free information and support to those with macular disease, along with their family and friends, to help people keep their independence.
Get the latest news and advice from the Macular Society
To hear about life-changing research, treatments and tips for living with sight loss, subscribe to our monthly enewsletter today. Together we can Beat Macular Disease.Sign up to our free email newsletter